Zepbound beats Wegovy in study of weight-loss medications

Zepbound beats Wegovy in study of weight-loss medications

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

This drug led to 50% more weight loss than Wegovy in head-to-head study – Advertising and Donations – advertising-newsandtimes.com

When it comes to shedding pounds and cinching inches, a new study puts one weight loss drug ahead of another.